{
    "clinical_study": {
        "@rank": "1494", 
        "arm_group": {
            "arm_group_label": "induction TPF chemotherapy", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is a phase II study of preoperative chemotherapy with docetaxel, cisplatin and\n      5-fluorouracil (TPF) in locally advanced resectable oral cavity squamous cell cancer. The\n      aim is to improve the rate of pathological complete response to induction chemotherapy in a\n      molecular enriched population, consisting of patients with tumour harbouring a functional\n      p53 protein and/or showing low expression of beta-tubulin II."
        }, 
        "brief_title": "Preoperative TPF Chemotherapy in a Population of Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell Cancer", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Locally Advanced Resectable Oral Cavity Squamous Cell Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Squamous Cell", 
                "Neoplasms, Squamous Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed informed consent\n\n          -  Males and females age > 18 years\n\n          -  Histologically proved primary oral cavity squamous cell cancer (tumour extending to\n             oropharynx are accepted if oropharyngeal invasion is < 20% of the tumour size)\n\n          -  Stage T2 (T2 stage is accepted if tumour size is 3 cm or larger).-T3, N1- N3 and T4a\n             any N\n\n          -  WHO performance status < 1\n\n          -  Availability of block of Formalin Fixed Paraffin Embedded (FFPE) biopsy of the tumour\n\n          -  Radiological imaging of the tumour with MRI pre-therapy\n\n          -  Effective contraception for both male and female subjects if risk of conception\n             exists\n\n        Exclusion Criteria:\n\n          -  Prior antitumour therapy for head & neck cancer (chemotherapy or biological therapy\n             and radiotherapy)\n\n          -  Metastatic disease\n\n          -  Medical condition that contraindicate administration of TPF scheme, in particular:\n\n               1. clinically significant cardiac disease including unstable angina, acute\n                  myocardial infarction in the previous 2 years, congestive heart failure and\n                  arrhythmia requiring therapy\n\n               2. chronic or current infectious disease that contraindicate administration of\n                  chemotherapy causing neutropenia; known HIV, Hepatitis B or C positivity\n\n               3. uncontrolled renal, hepatic, neurological, cerebral, psychiatric,\n                  haematological, gastrointestinal, pulmonary, vascular or endocrine diseases that\n                  could interfere with antiblastic treatment\n\n          -  Pre-existing peripheral neuropathy according to Common Toxicity Criteria (CTC)\n             Adverse Event  grade > 1\n\n          -  Pre-existing ototoxicity grade > 1\n\n          -  Previous diagnosis of other cancer in the last 3 years (in situ cervical cancer or\n             completely excised basocellular/squamocellular skin cancer are always admitted )\n\n          -  Previous other cancer in oral cavity to less than 2 cm from existing primary\n\n          -  Breast feeding women or women with a positive pregnancy test at Visit 0 or 1\n\n          -  Screening laboratory values:\n\n               -  Neutrophils < 1.5 x 109/L\n\n               -  Platelets < 100 x 109/L\n\n               -  ALT or AST > 2.5 times upper limit of normal\n\n               -  Calculated creatinine clearance < 60 mL/min\n\n               -  Weight loss more than 20% in 3 months preceding the study\n\n               -  Technical unresectability defined as: T4b staging or N ulcerating the skin or\n                  encasing internal carotid"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "14", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01914900", 
            "org_study_id": "INT40/10"
        }, 
        "intervention": {
            "arm_group_label": "induction TPF chemotherapy", 
            "intervention_name": "docetaxel, cisplatin, 5 fluorouracil", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Docetaxel", 
                "Cisplatin", 
                "Fluorouracil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "oral cavity cancer", 
            "induction chemotherapy", 
            "TP53", 
            "beta tubulin II"
        ], 
        "lastchanged_date": "July 31, 2013", 
        "location": {
            "contact": {
                "email": "paolo.bossi@istitutotumori.mi.it", 
                "last_name": "Paolo Bossi, MD", 
                "phone": "+390223902765"
            }, 
            "facility": {
                "address": {
                    "city": "Milano", 
                    "country": "Italy", 
                    "zip": "20133"
                }, 
                "name": "Istituto Nazionale Tumori"
            }, 
            "investigator": {
                "last_name": "Lisa Licitra, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study of Preoperative TPF Chemotherapy in Locally Advanced Resectable Oral Cavity Squamous Cell Cancer in Order to Improve the Rate of Pathological Complete Response", 
        "overall_contact": {
            "email": "paolo.bossi@istitutotumori.mi.it", 
            "last_name": "Paolo Bossi, MD", 
            "phone": "+390223902765"
        }, 
        "overall_contact_backup": {
            "email": "lisa.licitra@istitutotumori.mi.it", 
            "last_name": "Lisa Licitra, MD", 
            "phone": "+390223902805"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "For what concerns primary endpoint of pathologic complete remission achievement, the patients will be assessed at time of surgery, i.e., after about 9 weeks since chemotherapy start.", 
            "measure": "pathologic complete remission", 
            "safety_issue": "No", 
            "time_frame": "After 9 weeks since chemotherapy start"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01914900"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fondazione IRCCS Istituto Nazionale dei Tumori, Milano", 
            "investigator_full_name": "Lisa Licitra", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Patients will be followed up to 5 years for what concerns PFS", 
                "measure": "Progression free survival", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "description": "Patients will be followed up to 5 years for what concerns OS", 
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "Compliance to induction chemotherapy", 
                "safety_issue": "Yes", 
                "time_frame": "9 weeks"
            }, 
            {
                "measure": "Percentage of patient receiving postoperative radiotherapy and chemotherapy", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "radiological evaluation after 1 cycle of induction chemotherapy", 
                "measure": "Early functional response evaluation by DWI and DCE MRI", 
                "safety_issue": "No", 
                "time_frame": "3 weeks"
            }, 
            {
                "description": "comparison between radiological assessment of response and pathological one", 
                "measure": "Comparison between (DWI - DCE) MRI response and pathological response", 
                "safety_issue": "No", 
                "time_frame": "9 weeks"
            }
        ], 
        "source": "Fondazione IRCCS Istituto Nazionale dei Tumori, Milano", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fondazione IRCCS Istituto Nazionale dei Tumori, Milano", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}